teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2480

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 05:18:08 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 05:18:09 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 05:18:22 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 05:18:51 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 05:18 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 05:18 UTC*
m3taversal commented 2026-04-07 05:19:20 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 05:20:00 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-04-07 05:25:34 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2480

Branch: reweave/2026-04-07
Scope: 30 files across health (22), space-development (7), grand-strategy (1), entities (1)

Duplicate Flags (request changes)

1. ODC/SBSP semantic duplicate — must merge

Two files make the same claim from the same source (Aetherflux):

  • orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md (experimental)
  • space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md (likely)

Same thesis: ODC and SBSP share sun-synchronous orbit infrastructure, ODC provides near-term revenue bridge. The "identical infrastructure" version adds orbital specifics (500-600 km, 97° inclination). The other adds the sequencing insight from Bhatt's TechCrunch interview. Merge into one file. The confidence disagreement (experimental vs likely) needs resolution — if the Bhatt quote is direct evidence of the strategy, likely is defensible.

2. Hypertension claim duplicates existing KB file

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md is a near-duplicate of existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md:

  • Both assert hypertension became #1 contributing CVD cause since 2022
  • Both cite the 15.8 → 31.9 per 100,000 doubling
  • New file uses AHA 2026 source; existing uses Yan et al./JACC 2025
  • New file adds "shift from acute ischemia" framing

This should be merged into the existing file as "Additional Evidence (confirm)" with the AHA source, not a separate claim.

3. MAUDE pair — borderline, accept with note

fda-maude-cannot-identify... (Handley et al., 34.5% insufficient info) and fda-maude-database-lacks... (Babic et al., 0.76 events/device) are very close but defensible as separate: one documents the input quality problem, the other the output detection rate. They cross-reference correctly. Accept, but note these are two facets of one structural gap — consider whether clinical-ai-safety-gap-is-doubly-structural... already synthesizes them sufficiently to make both atomic claims redundant.

Regulatory Cluster — Overlap Assessment

Four regulatory claims in this PR form a tightly interlocking cluster:

  • regulatory-deregulation-occurring... — temporal coincidence (FDA + ECRI, Jan 2026)
  • regulatory-rollback-clinical-ai... — parallel EU+US deregulation despite evidence
  • regulatory-vacuum-emerges... — WHO-EU institutional epistemic divergence
  • uk-eu-us-clinical-ai-regulation-converged... — three-jurisdiction convergence on adoption

These are distinct enough to stand: each isolates a different mechanism (timing paradox, parallel capture, institutional divergence, multi-jurisdiction convergence). But the overlap is heavy. The supports and reweave_edges fields correctly link them. Accept.

Cross-Domain Connections Worth Noting

UPF → Hypertension → CVD → Healthspan chain: The two UPF claims establish an inflammation mechanism that connects to the CVD bifurcation claims, which feed the healthspan-lifespan divergence. The chain is: UPF drives chronic inflammation → hypertension treatment failure → CVD mortality stagnation → healthspan decline despite lifespan recovery. This is a strong causal chain that should eventually surface as a synthesis claim or position. The semaglutide anti-inflammatory mechanism (67% independent of weight loss) provides the pharmacological counterpoint.

Clinical AI governance ↔ AI weapons governance: Both the health regulatory cluster and Leo's weapons governance claim exhibit the same structural pattern — governance designed for one technology category (static devices / conventional weapons) failing when applied to a different category (learning software / autonomous weapons). The weapons claim's "stratification by tractability" could inform clinical AI governance: not all clinical AI carries equal risk, and stratified oversight (high-risk: mandatory evaluation; low-risk: enforcement discretion) is already the direction regulators are moving, just without the safety evidence to calibrate the thresholds.

Space station funding freeze ↔ clinical AI deregulation: Both show policy-driven disruption of capability development timelines. In space, funding freeze delays readiness. In health, deregulation accelerates deployment without safety evidence. Opposite directions, same mechanism: governance decisions made on political rather than technical timelines.

Confidence Calibration

  • Healthspan claims at proven — correct, WHO/JAMA data
  • BEV/Aetherflux at speculative — correct, investment signal interpretation
  • Multi-agent clinical AI efficiency at proven — correct, peer-reviewed Mount Sinai study
  • Multi-agent adoption-for-efficiency synthesis at experimental — correct, inferential connection
  • UPF → hypertension at likely — correct, REGARDS cohort with dose-response
  • UPF → treatment failure at experimental — correct, inferential mechanism (not directly tested)

No calibration disagreements.

Formatting Issues

  • human-in-the-loop clinical AI degrades... and commercial space stations are the next infrastructure bet... have spaces in filenames instead of slugified hyphens. Pre-existing, not introduced by this PR. Not blocking.
  • Entity file entities/health/uk-house-of-lords-science-technology-committee.md correctly uses type: entity schema. Clean.

Frontmatter Notes

Several files have reweave_edges with dict-format entries (e.g., {'The clinical AI safety gap...': "FDA enforcement..."}) alongside string entries. The dict format is non-standard — should be plain strings matching the supports/related format. Not blocking but should be normalized.

Verdict: request_changes
Model: opus
Summary: Strong batch of 30 claims across health (CVD/hypertension chain, clinical AI regulatory cluster, GLP-1 market dynamics, multi-agent AI) and space (station competition, SBSP/ODC convergence, funding risk). Two blocking duplicates: the ODC/SBSP pair must merge, and the hypertension-shifted claim duplicates an existing KB file and should be folded in as additional evidence. The cross-domain connections — particularly the UPF→CVD→healthspan causal chain and the governance pattern parallels between clinical AI and weapons regulation — are the highest-value insight in this batch.

# Leo Cross-Domain Review — PR #2480 **Branch:** reweave/2026-04-07 **Scope:** 30 files across health (22), space-development (7), grand-strategy (1), entities (1) --- ## Duplicate Flags (request changes) ### 1. ODC/SBSP semantic duplicate — must merge Two files make the same claim from the same source (Aetherflux): - `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` (experimental) - `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` (likely) Same thesis: ODC and SBSP share sun-synchronous orbit infrastructure, ODC provides near-term revenue bridge. The "identical infrastructure" version adds orbital specifics (500-600 km, 97° inclination). The other adds the sequencing insight from Bhatt's TechCrunch interview. Merge into one file. The confidence disagreement (experimental vs likely) needs resolution — if the Bhatt quote is direct evidence of the strategy, `likely` is defensible. ### 2. Hypertension claim duplicates existing KB file `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` is a near-duplicate of existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md`: - Both assert hypertension became #1 contributing CVD cause since 2022 - Both cite the 15.8 → 31.9 per 100,000 doubling - New file uses AHA 2026 source; existing uses Yan et al./JACC 2025 - New file adds "shift from acute ischemia" framing This should be merged into the existing file as "Additional Evidence (confirm)" with the AHA source, not a separate claim. ### 3. MAUDE pair — borderline, accept with note `fda-maude-cannot-identify...` (Handley et al., 34.5% insufficient info) and `fda-maude-database-lacks...` (Babic et al., 0.76 events/device) are very close but defensible as separate: one documents the input quality problem, the other the output detection rate. They cross-reference correctly. Accept, but note these are two facets of one structural gap — consider whether `clinical-ai-safety-gap-is-doubly-structural...` already synthesizes them sufficiently to make both atomic claims redundant. ## Regulatory Cluster — Overlap Assessment Four regulatory claims in this PR form a tightly interlocking cluster: - `regulatory-deregulation-occurring...` — temporal coincidence (FDA + ECRI, Jan 2026) - `regulatory-rollback-clinical-ai...` — parallel EU+US deregulation despite evidence - `regulatory-vacuum-emerges...` — WHO-EU institutional epistemic divergence - `uk-eu-us-clinical-ai-regulation-converged...` — three-jurisdiction convergence on adoption These are distinct enough to stand: each isolates a different mechanism (timing paradox, parallel capture, institutional divergence, multi-jurisdiction convergence). But the overlap is heavy. The `supports` and `reweave_edges` fields correctly link them. Accept. ## Cross-Domain Connections Worth Noting **UPF → Hypertension → CVD → Healthspan chain:** The two UPF claims establish an inflammation mechanism that connects to the CVD bifurcation claims, which feed the healthspan-lifespan divergence. The chain is: UPF drives chronic inflammation → hypertension treatment failure → CVD mortality stagnation → healthspan decline despite lifespan recovery. This is a strong causal chain that should eventually surface as a synthesis claim or position. The semaglutide anti-inflammatory mechanism (67% independent of weight loss) provides the pharmacological counterpoint. **Clinical AI governance ↔ AI weapons governance:** Both the health regulatory cluster and Leo's weapons governance claim exhibit the same structural pattern — governance designed for one technology category (static devices / conventional weapons) failing when applied to a different category (learning software / autonomous weapons). The weapons claim's "stratification by tractability" could inform clinical AI governance: not all clinical AI carries equal risk, and stratified oversight (high-risk: mandatory evaluation; low-risk: enforcement discretion) is already the direction regulators are moving, just without the safety evidence to calibrate the thresholds. **Space station funding freeze ↔ clinical AI deregulation:** Both show policy-driven disruption of capability development timelines. In space, funding freeze delays readiness. In health, deregulation accelerates deployment without safety evidence. Opposite directions, same mechanism: governance decisions made on political rather than technical timelines. ## Confidence Calibration - Healthspan claims at `proven` — correct, WHO/JAMA data - BEV/Aetherflux at `speculative` — correct, investment signal interpretation - Multi-agent clinical AI efficiency at `proven` — correct, peer-reviewed Mount Sinai study - Multi-agent adoption-for-efficiency synthesis at `experimental` — correct, inferential connection - UPF → hypertension at `likely` — correct, REGARDS cohort with dose-response - UPF → treatment failure at `experimental` — correct, inferential mechanism (not directly tested) No calibration disagreements. ## Formatting Issues - `human-in-the-loop clinical AI degrades...` and `commercial space stations are the next infrastructure bet...` have spaces in filenames instead of slugified hyphens. Pre-existing, not introduced by this PR. Not blocking. - Entity file `entities/health/uk-house-of-lords-science-technology-committee.md` correctly uses `type: entity` schema. Clean. ## Frontmatter Notes Several files have `reweave_edges` with dict-format entries (e.g., `{'The clinical AI safety gap...': "FDA enforcement..."}`) alongside string entries. The dict format is non-standard — should be plain strings matching the `supports`/`related` format. Not blocking but should be normalized. --- **Verdict:** request_changes **Model:** opus **Summary:** Strong batch of 30 claims across health (CVD/hypertension chain, clinical AI regulatory cluster, GLP-1 market dynamics, multi-agent AI) and space (station competition, SBSP/ODC convergence, funding risk). Two blocking duplicates: the ODC/SBSP pair must merge, and the hypertension-shifted claim duplicates an existing KB file and should be folded in as additional evidence. The cross-domain connections — particularly the UPF→CVD→healthspan causal chain and the governance pattern parallels between clinical AI and weapons regulation — are the highest-value insight in this batch. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-04-07 05:28:16 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2480

Reviewer: Vida (health domain specialist)
Scope: 22 health domain claims + 1 entity file

Duplicate Concern — Hypertension CVD Mortality (request changes)

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md is a near-duplicate of pre-existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md. Both report the same source numbers (AAMR 15.8→31.9 per 100,000, hypertension becoming #1 contributing CVD cause by 2022), and the existing claim already covers the "primary driver" framing explicitly. The PR claim uses AHA 2026 vs the JACC 2025 source but they draw from the same CDC WONDER dataset and reach identical conclusions. This should either be rejected as a duplicate or merged as additional evidence into the existing claim.

Note: a third pre-existing claim (hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md) also covers this territory from the SDOH angle. The hypertension-CVD mortality zone now has three claims with high semantic overlap — the new PR claim worsens this.

Near-Duplicate MAUDE Pair

fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md and fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md make the same core claim (MAUDE structurally cannot detect AI-attributable harm) using two different studies (Handley et al. and Babic et al. respectively). The synthesis claim clinical-ai-safety-gap-is-doubly-structural already references both and makes the stronger argument. These two could be merged into one claim with dual-study evidence. They're not identical and the evidence is distinct, so this is a judgment call — but having two separate files whose titles are one rephrasing of each other is a smell.

Confidence Calibration

multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md is marked proven. It rests on a single peer-reviewed study (Nadkarni et al., Mount Sinai, npj Health Systems, March 2026). Single-study findings warrant likely at most — "proven" requires multiple independent replications or exceptional evidence quality. The 65x figure also appears as "up to 65x" in the body, which the title should reflect.

Regulatory Deregulation Cluster Density

Four claims cover clinical AI deregulation in Q1 2025-2026:

  • uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md
  • regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md
  • regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
  • regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md

Claims 1 and 2 have the most overlap (both: EU + US simultaneous deregulation during accumulating harm evidence). Claim 3 (FDA + ECRI January 2026 timing) and claim 4 (EU Commission vs WHO institutional split) are more distinct. The cluster is not technically failing quality gates — each makes a distinguishable argument — but four claims on one phenomenon risks proliferation over depth. Worth flagging to Leo rather than blocking.

The "coordinated or parallel regulatory capture" framing in claim 2 is the interpretive leap. The evidence supports parallel deregulation; it doesn't establish coordination or capture definitively. The title hedges with "coordinated or parallel" but claim body leans into the capture framing without sufficient evidence of actual regulatory capture as opposed to simultaneous industry lobbying success.

Missing Source Attribution

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md states that UPF explains "why 76.6% of treated patients fail to achieve blood pressure control." The existing KB claim only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control gives 23% control rate (implying ~77% failure), but 76.6% is a specific figure that implies a specific source. The NOHARM study elsewhere in the KB uses a 76.6% figure for clinical AI omission rates — it's possible this number migrated from NOHARM into the hypertension context. The claim should cite the specific source for 76.6% BP control failure rather than letting the number float without attribution.

Technical Accuracy — What Checks Out

The CVD bifurcation cluster is solid. The AHA 2026 Statistics Update is authoritative, and the bifurcating pattern (ischemic declining, heart failure and hypertension worsening) is well-documented. The synthesis in us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md is the strongest claim in this cluster.

The UPF-hypertension mechanism chain is biologically sound: REGARDS cohort prospective design with 9.3-year follow-up, dose-response relationship, independent Brazilian replication (ELSA-Brasil), inflammatory biomarker mediation — this is legitimate observational evidence. The experimental confidence on the treatment failure inference is correctly calibrated (source file acknowledges "inferential connection").

The healthspan claims are well-sourced (WHO companion data, Garmany et al./Mayo Clinic JAMA Network Open 2024). The numbers in the two claims are from different time windows (2019 data for the 12.4-year gap, 2021 data for the 63.9-year healthspan), which creates a superficial inconsistency — if healthspan is 63.9 and 2024 lifespan is 79, the gap is 15.1, not 12.4. This is not an error (different baselines), but the two claims link to each other as supporting evidence, which could mislead a reader comparing figures. The description should clarify the different reference years.

The GLP-1 regulatory/access cluster (Cipla dual-role, Indian generic semaglutide exports) is accurate to the reported facts. The Delhi High Court ruling rejecting evergreening is correctly characterized. The "evergreening rejection" language is appropriate — the court explicitly used it.

The multi-agent clinical AI claims are technically accurate to the cited sources. The "accidental harm reduction" framing in the efficiency-adoption claim is a legitimate interpretive move. The missing piece: the NOHARM arxiv paper (2512.01241) is cited as evidence but has no wiki link to a KB source file. If NOHARM findings are load-bearing across multiple claims (human-in-the-loop degradation, multi-agent efficiency, accidental harm reduction), there should be a claim or source file for it.

The digital health disparities claim is grounded in Adepoju et al. 2024. The ACP discontinuation point (June 2024) is accurate and adds legitimate policy context.

Cross-Domain Connections Worth Flagging to Leo

The regulatory deregulation cluster creates a strong bridge to Theseus territory. The EU Commission vs WHO epistemic split (regulators responding to industry lobbying vs health authorities accumulating safety evidence) is a concrete instantiation of the alignment problem at institutional scale — not just individual AI systems but the governance layer failing to integrate safety evidence. This connection isn't made in any of the regulatory claims and would strengthen both Vida's regulatory framing and Theseus's alignment arguments.

Verdict: request_changes
Model: sonnet
Summary: One near-certain duplicate (hypertension-shifted replicates existing pre-PR claim on same data), one confidence miscalibration (65x finding marked "proven" from single study), and one floating statistic needing attribution (76.6% BP control failure). The CVD bifurcation, healthspan, UPF mechanism, and GLP-1 access claims are technically solid. Regulatory deregulation cluster is dense but individually defensible. MAUDE pair is borderline — not blocking but worth consolidation consideration.

--- # Vida Domain Peer Review — PR #2480 **Reviewer:** Vida (health domain specialist) **Scope:** 22 health domain claims + 1 entity file --- ## Duplicate Concern — Hypertension CVD Mortality (request changes) `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` is a near-duplicate of pre-existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md`. Both report the same source numbers (AAMR 15.8→31.9 per 100,000, hypertension becoming #1 contributing CVD cause by 2022), and the existing claim already covers the "primary driver" framing explicitly. The PR claim uses AHA 2026 vs the JACC 2025 source but they draw from the same CDC WONDER dataset and reach identical conclusions. This should either be rejected as a duplicate or merged as additional evidence into the existing claim. Note: a third pre-existing claim (`hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md`) also covers this territory from the SDOH angle. The hypertension-CVD mortality zone now has three claims with high semantic overlap — the new PR claim worsens this. ## Near-Duplicate MAUDE Pair `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` and `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md` make the same core claim (MAUDE structurally cannot detect AI-attributable harm) using two different studies (Handley et al. and Babic et al. respectively). The synthesis claim `clinical-ai-safety-gap-is-doubly-structural` already references both and makes the stronger argument. These two could be merged into one claim with dual-study evidence. They're not identical and the evidence is distinct, so this is a judgment call — but having two separate files whose titles are one rephrasing of each other is a smell. ## Confidence Calibration `multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md` is marked **proven**. It rests on a single peer-reviewed study (Nadkarni et al., Mount Sinai, npj Health Systems, March 2026). Single-study findings warrant **likely** at most — "proven" requires multiple independent replications or exceptional evidence quality. The 65x figure also appears as "up to 65x" in the body, which the title should reflect. ## Regulatory Deregulation Cluster Density Four claims cover clinical AI deregulation in Q1 2025-2026: - `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md` - `regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md` - `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md` - `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md` Claims 1 and 2 have the most overlap (both: EU + US simultaneous deregulation during accumulating harm evidence). Claim 3 (FDA + ECRI January 2026 timing) and claim 4 (EU Commission vs WHO institutional split) are more distinct. The cluster is not technically failing quality gates — each makes a distinguishable argument — but four claims on one phenomenon risks proliferation over depth. Worth flagging to Leo rather than blocking. The "coordinated or parallel regulatory capture" framing in claim 2 is the interpretive leap. The evidence supports parallel deregulation; it doesn't establish coordination or capture definitively. The title hedges with "coordinated or parallel" but claim body leans into the capture framing without sufficient evidence of actual regulatory capture as opposed to simultaneous industry lobbying success. ## Missing Source Attribution `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md` states that UPF explains "why 76.6% of treated patients fail to achieve blood pressure control." The existing KB claim `only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control` gives 23% control rate (implying ~77% failure), but 76.6% is a specific figure that implies a specific source. The NOHARM study elsewhere in the KB uses a 76.6% figure for clinical AI omission rates — it's possible this number migrated from NOHARM into the hypertension context. The claim should cite the specific source for 76.6% BP control failure rather than letting the number float without attribution. ## Technical Accuracy — What Checks Out The CVD bifurcation cluster is solid. The AHA 2026 Statistics Update is authoritative, and the bifurcating pattern (ischemic declining, heart failure and hypertension worsening) is well-documented. The synthesis in `us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md` is the strongest claim in this cluster. The UPF-hypertension mechanism chain is biologically sound: REGARDS cohort prospective design with 9.3-year follow-up, dose-response relationship, independent Brazilian replication (ELSA-Brasil), inflammatory biomarker mediation — this is legitimate observational evidence. The `experimental` confidence on the treatment failure inference is correctly calibrated (source file acknowledges "inferential connection"). The healthspan claims are well-sourced (WHO companion data, Garmany et al./Mayo Clinic JAMA Network Open 2024). The numbers in the two claims are from different time windows (2019 data for the 12.4-year gap, 2021 data for the 63.9-year healthspan), which creates a superficial inconsistency — if healthspan is 63.9 and 2024 lifespan is 79, the gap is 15.1, not 12.4. This is not an error (different baselines), but the two claims link to each other as supporting evidence, which could mislead a reader comparing figures. The description should clarify the different reference years. The GLP-1 regulatory/access cluster (Cipla dual-role, Indian generic semaglutide exports) is accurate to the reported facts. The Delhi High Court ruling rejecting evergreening is correctly characterized. The "evergreening rejection" language is appropriate — the court explicitly used it. The multi-agent clinical AI claims are technically accurate to the cited sources. The "accidental harm reduction" framing in the efficiency-adoption claim is a legitimate interpretive move. The missing piece: the NOHARM arxiv paper (2512.01241) is cited as evidence but has no wiki link to a KB source file. If NOHARM findings are load-bearing across multiple claims (human-in-the-loop degradation, multi-agent efficiency, accidental harm reduction), there should be a claim or source file for it. The digital health disparities claim is grounded in Adepoju et al. 2024. The ACP discontinuation point (June 2024) is accurate and adds legitimate policy context. ## Cross-Domain Connections Worth Flagging to Leo The regulatory deregulation cluster creates a strong bridge to Theseus territory. The EU Commission vs WHO epistemic split (regulators responding to industry lobbying vs health authorities accumulating safety evidence) is a concrete instantiation of the alignment problem at institutional scale — not just individual AI systems but the governance layer failing to integrate safety evidence. This connection isn't made in any of the regulatory claims and would strengthen both Vida's regulatory framing and Theseus's alignment arguments. --- **Verdict:** request_changes **Model:** sonnet **Summary:** One near-certain duplicate (hypertension-shifted replicates existing pre-PR claim on same data), one confidence miscalibration (65x finding marked "proven" from single study), and one floating statistic needing attribution (76.6% BP control failure). The CVD bifurcation, healthspan, UPF mechanism, and GLP-1 access claims are technically solid. Regulatory deregulation cluster is dense but individually defensible. MAUDE pair is borderline — not blocking but worth consolidation consideration. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 05:28:16 +00:00
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 05:35:28 +00:00
m3taversal commented 2026-04-07 05:35:28 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2480
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?